Akari Therapeutics PLC

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Show More...

  • Website https://www.akaritx.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.35 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -5.05 -15.85 -35.0 -17.0 -2.0 -5.0 -2.0 -3.0 -1.0 -1.0 -0.97
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 9.0 12.0 12.0 15.0 18.0 21.0
    Book Value Per Share * USD -8.35 10.45 3.51 3.48 0.85 0.4 0.14 0.06
    Free Cash Flow Per Share * USD -5.3 -25.86 -1.24 -2.12 -2.52 -1.76 -0.83
    Return on Assets % -250.22 -80.88 -134.82 -118.67 -31.34 -94.49 -88.82 -230.67 -191.13
    Financial Leverage (Average) 1.35 1.34 1.43 1.35 1.69 2.58 5.49
    Return on Equity % -295.03 -180.89 -169.18 -43.81 -138.13 -162.51
    Return on Invested Capital % -278.57 -180.89 -157.86 -44.15 -138.81 -164.71
    Interest Coverage -16.92 -13.84
    Current Ratio 0.010 0.29 6.36 4.73 3.3 3.9 2.43 1.52 0.79 1.22
    Quick Ratio 0.010 0.29 6.36 4.63 3.26 3.77 2.37 1.11 0.67 0.96
    Debt/Equity